Your browser doesn't support javascript.
loading
The effects and mechanisms of modified Xiaoyaosan on chronic unpredictable mild stress (CUMS)-induced depressive mice based on network pharmacology.
Liu, Yuan; Guo, Dong; Yu, Bin; Zeng, Ting; Jiao, Feng-Li; Bi, Yan-Meng.
Afiliação
  • Liu Y; College of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, China.
  • Guo D; College of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, China.
  • Yu B; College of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, China.
  • Zeng T; Department of Neurology, The Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou, China.
  • Jiao FL; Department of Acupuncture and Moxibustion, Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
  • Bi YM; College of Integrated Traditional Chinese and Western Medicine, Jining Medical University, Jining, China. Electronic address: biyanmeng1984@mail.jnmc.edu.cn.
J Ethnopharmacol ; 324: 117754, 2024 Apr 24.
Article em En | MEDLINE | ID: mdl-38232859
ABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE Clinical research and basic scientific experiments have shown that modified Xiaoyaosan (MXYS) has antidepressant effects, whose system mechanism however has not been thoroughly characterized. AIM OF THE STUDY This research was aimed at evaluating the treatment effects of MXYS on chronic unpredictable mild stress (CUMS)-induced depressive mice and exploring underlying mechanisms. MATERIALS AND

METHODS:

Whether MXYS has effects on depression was investigated via the depressive behaviors of mice, electron microscopy, real-time quantitative polymerase chain reaction (RT-qPCR), Western blot analysis, immunofluorescence (IF) staining and the stereotaxic injection of adeno-associated viruses (AAVs). In addition, network pharmacology was applied to predict relevant molecular targets and possible mechanisms and perform further in vivo validation.

RESULTS:

MXYS is effective in ameliorating the depression-like symptoms of CUMS mice. It can stimulate autophagosome formation, activate the expression of microtubule-associated protein 1 light chain 3 (LC3B), autophagy-related gene 5 (Atg5), Atg7 and neuron-specific nuclear protein (NeuN), and decrease the protein expression sequestosome 1 (SQSTM1/p62). The autophagy-upregulating effect of MXYS was weakened by silencing. The network pharmacology analysis revealed that mitogen-activated protein kinase 1 (MAPK1), MAPK3, serine/threonine-protein kinase (AKT1), proto-oncogene tyrosine-protein kinase (SRC), PI 3 kinase p85 alpha (PIK3R1), catenin (cadherin-associated protein) beta 1 (CTNNB1) and human thrombin activator 1 (HRAS) may be of importance to treat depression by MXYS. Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis revealed that metabolic and autophagy pathways, pathways in cancer and MAPK, phosphoinositide 3-kinase (PI3K)-Akt and rhoptry-associated protein 1 (Rap1) signaling pathways are involved in the antidepressant effects of MXYS. As suggested by Western blot, the anti-depression mechanism of MXYS is possibly associated with the extracellular signal-regulated protein kinase (ERK)/P38 MAPK signaling pathway.

CONCLUSION:

The findings indicate the possible antidepressant effects of MXYS on CUMS mice via triggering autophagy to alleviate neuronal apoptosis and prompting autophagy, which may involve the ERK/P38 MAPK signaling pathway.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Fosfatidilinositol 3-Quinases / Depressão Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Ethnopharmacol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Medicamentos de Ervas Chinesas / Fosfatidilinositol 3-Quinases / Depressão Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: J Ethnopharmacol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China